Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00506142
Status:
COMPLETED
Last Update Posted:
2019-12-11
First Post:
2007-07-23
Brief Title:
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Sponsor:
Spectrum Pharmaceuticals Inc
Organization:
Spectrum Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Marqibo liposomal vincristine is a form of vincristine preparation Vincristine is designed to interfere with the multiplication of cancer cells which may slow or stop their growing and spreading throughout the body This may cause the cancer cells to die Liposomal vincristine is formed when vincristine is placed inside of oil droplets called liposomes which may help to improve the delivery of drug to the tumor site The liposomal formulation results in a slow steady release of vincristine in the tumor metastasis exposing the cancer cells to vincristine continuously
The goal of this clinical research study is to learn if Marqibo liposomal vincristine can help to control metastatic uveal melanoma The safety of liposomal vincristine will also be studied
Approximately 50 patients will take part in this study
The goal of this clinical research study is to learn if Marqibo liposomal vincristine can help to control metastatic uveal melanoma The safety of liposomal vincristine will also be studied
Approximately 50 patients will take part in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None